AU2014207716B2 - Bcl-2Bcl-xL inhibitors and therapeutic methods using the same - Google Patents
Bcl-2Bcl-xL inhibitors and therapeutic methods using the same Download PDFInfo
- Publication number
- AU2014207716B2 AU2014207716B2 AU2014207716A AU2014207716A AU2014207716B2 AU 2014207716 B2 AU2014207716 B2 AU 2014207716B2 AU 2014207716 A AU2014207716 A AU 2014207716A AU 2014207716 A AU2014207716 A AU 2014207716A AU 2014207716 B2 AU2014207716 B2 AU 2014207716B2
- Authority
- AU
- Australia
- Prior art keywords
- bcl
- nsc
- compound
- inhibitors
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753066P | 2013-01-16 | 2013-01-16 | |
| US61/753,066 | 2013-01-16 | ||
| PCT/US2014/011571 WO2014113413A1 (en) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014207716A1 AU2014207716A1 (en) | 2015-07-23 |
| AU2014207716B2 true AU2014207716B2 (en) | 2017-07-27 |
Family
ID=51165292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014207716A Active AU2014207716B2 (en) | 2013-01-16 | 2014-01-15 | Bcl-2Bcl-xL inhibitors and therapeutic methods using the same |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9096625B2 (OSRAM) |
| EP (2) | EP3689886A1 (OSRAM) |
| JP (1) | JP6347793B2 (OSRAM) |
| KR (2) | KR102210316B1 (OSRAM) |
| CN (3) | CN110302205B (OSRAM) |
| AU (1) | AU2014207716B2 (OSRAM) |
| CA (1) | CA2897055C (OSRAM) |
| ES (1) | ES2819232T3 (OSRAM) |
| HK (1) | HK1219734A1 (OSRAM) |
| NZ (1) | NZ709635A (OSRAM) |
| SG (1) | SG11201505525UA (OSRAM) |
| WO (1) | WO2014113413A1 (OSRAM) |
| ZA (1) | ZA201504902B (OSRAM) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2897055C (en) * | 2013-01-16 | 2021-04-20 | The Regents Of The University Of Michigan | Substituted 2-(trifluoromethylsulfonyl)phenylamino compounds and pharmaceutical compositions thereof as bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| WO2015171591A1 (en) | 2014-05-05 | 2015-11-12 | Board Of Trustees Of The University Of Arkansas | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| EP3177144A4 (en) | 2014-07-22 | 2018-01-24 | Bioventures, LLC. | Compositions and methods for selectively depleting senescent cells |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| HK1249030A1 (zh) * | 2015-02-06 | 2018-10-26 | Unity Biotechnology, Inc. | 化合物及在治疗衰老相关病症中的用途 |
| WO2017101851A1 (en) * | 2015-12-18 | 2017-06-22 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| KR102599512B1 (ko) | 2016-03-28 | 2023-11-07 | 프레시지 바이오싸이언시스, 인크. | 암 치료를 위한 제약학적 조합물 |
| KR102447884B1 (ko) * | 2016-04-21 | 2022-09-27 | 바이오벤처스, 엘엘씨 | 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도 |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| US20200354336A9 (en) * | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| WO2019033119A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| CA3043103C (en) | 2017-12-30 | 2021-02-09 | Unity Biotechnology | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| WO2019139902A1 (en) | 2018-01-10 | 2019-07-18 | Zeno Royalties & Milestones, LLC | Benzamide compounds |
| CA3088253A1 (en) * | 2018-01-22 | 2019-07-25 | Bioventures, Llc | Bcl-2 proteins degraders for cancer treatment |
| JP2021521138A (ja) | 2018-04-29 | 2021-08-26 | ベイジーン リミテッド | Ｂｃｌ−２阻害剤 |
| CN117866015A (zh) | 2018-04-30 | 2024-04-12 | 联合生物科技公司 | 一种临床管理中使用的化合物及其用途 |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US11491168B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof |
| AU2019314624B2 (en) | 2018-07-31 | 2022-03-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| MX2020009759A (es) | 2018-07-31 | 2020-10-08 | Ascentage Pharma Suzhou Co Ltd | Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop. |
| CA3095699A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| EP3829593A4 (en) * | 2018-07-31 | 2022-04-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof |
| US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| US11872237B2 (en) * | 2018-12-28 | 2024-01-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and preparation method thereof |
| US11370807B2 (en) | 2019-01-04 | 2022-06-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Process for preparing sulfonamide compounds |
| WO2020140957A1 (en) * | 2019-01-04 | 2020-07-09 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| WO2021000899A1 (en) * | 2019-07-02 | 2021-01-07 | Ascentage Pharma (Suzhou) Co., Ltd. | A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF |
| WO2021018240A1 (en) * | 2019-07-31 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CN112852959A (zh) * | 2019-11-27 | 2021-05-28 | 苏州亚盛药业有限公司 | 用于预测靶向细胞凋亡途径的化合物的抗癌功效的方法和组合物 |
| CN112891353B (zh) * | 2019-12-04 | 2024-01-30 | 苏州亚盛药业有限公司 | 药物组合及其用途 |
| US20230025865A1 (en) * | 2019-12-11 | 2023-01-26 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS |
| CN113350281B (zh) * | 2020-03-02 | 2023-08-15 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| TWI776451B (zh) * | 2020-04-10 | 2022-09-01 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2/bcl-xl抑制劑之組合及相關用途 |
| AU2021256580A1 (en) | 2020-04-15 | 2022-09-29 | Beone Medicines I Gmbh | Bcl-2 inhibitor |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| WO2022008464A1 (en) | 2020-07-06 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| CN113929715A (zh) * | 2020-07-13 | 2022-01-14 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂化合物或其盐的结晶形式或无定形形式 |
| CN114053288B (zh) * | 2020-07-31 | 2024-11-19 | 苏州亚盛药业有限公司 | 肺部疾病治疗的组合物和方法 |
| KR20230145313A (ko) * | 2020-11-10 | 2023-10-17 | 유니티 바이오테크놀로지, 인크. | Bcl의 결정성 고체 메글루민 염 억제제 및 이의 제조 방법 및 이의 사용 방법 |
| WO2022111647A1 (en) * | 2020-11-27 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof |
| WO2022120114A1 (en) | 2020-12-04 | 2022-06-09 | University Of Notre Dame Du Lac | Method of encapsulating single cells utilizing an alternating current electrospray |
| JP2024528174A (ja) * | 2021-08-02 | 2024-07-26 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 医薬組合せおよびその使用 |
| TW202415653A (zh) * | 2022-08-02 | 2024-04-16 | 大陸商北京星奇原生物科技有限公司 | Ｂｃｌ－ｘｌ降解化合物 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012103059A2 (en) * | 2011-01-25 | 2012-08-02 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| AU2005277223C1 (en) | 2004-08-20 | 2009-05-21 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof |
| CA2606147C (en) | 2005-05-12 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US20070197532A1 (en) | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| JP5277168B2 (ja) * | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| BRPI0916356B1 (pt) | 2008-07-24 | 2022-08-23 | Nerviano Medical Sciences S.R.L | 3,4-diaril pirazois como inibidores da proteína quinase |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| CA2897055C (en) * | 2013-01-16 | 2021-04-20 | The Regents Of The University Of Michigan | Substituted 2-(trifluoromethylsulfonyl)phenylamino compounds and pharmaceutical compositions thereof as bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
-
2014
- 2014-01-15 CA CA2897055A patent/CA2897055C/en active Active
- 2014-01-15 AU AU2014207716A patent/AU2014207716B2/en active Active
- 2014-01-15 ES ES14741180T patent/ES2819232T3/es active Active
- 2014-01-15 CN CN201910634742.2A patent/CN110302205B/zh active Active
- 2014-01-15 HK HK16107756.1A patent/HK1219734A1/zh unknown
- 2014-01-15 NZ NZ70963514A patent/NZ709635A/en unknown
- 2014-01-15 US US14/155,809 patent/US9096625B2/en active Active
- 2014-01-15 CN CN201910634723.XA patent/CN110305162A/zh active Pending
- 2014-01-15 EP EP20163914.3A patent/EP3689886A1/en not_active Withdrawn
- 2014-01-15 WO PCT/US2014/011571 patent/WO2014113413A1/en not_active Ceased
- 2014-01-15 EP EP14741180.5A patent/EP2945940B1/en active Active
- 2014-01-15 SG SG11201505525UA patent/SG11201505525UA/en unknown
- 2014-01-15 KR KR1020157021823A patent/KR102210316B1/ko active Active
- 2014-01-15 KR KR1020207037597A patent/KR102318204B1/ko active Active
- 2014-01-15 CN CN201480015733.0A patent/CN105246882A/zh active Pending
- 2014-01-15 JP JP2015553788A patent/JP6347793B2/ja active Active
-
2015
- 2015-07-08 ZA ZA2015/04902A patent/ZA201504902B/en unknown
- 2015-08-03 US US14/816,191 patent/US9403856B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012103059A2 (en) * | 2011-01-25 | 2012-08-02 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110302205B (zh) | 2020-06-09 |
| NZ709635A (en) | 2019-10-25 |
| US9096625B2 (en) | 2015-08-04 |
| JP6347793B2 (ja) | 2018-06-27 |
| KR102318204B1 (ko) | 2021-10-26 |
| KR20150104631A (ko) | 2015-09-15 |
| KR20210002126A (ko) | 2021-01-06 |
| EP2945940A1 (en) | 2015-11-25 |
| US20140199234A1 (en) | 2014-07-17 |
| CA2897055C (en) | 2021-04-20 |
| KR102210316B1 (ko) | 2021-01-29 |
| SG11201505525UA (en) | 2015-08-28 |
| ES2819232T3 (es) | 2021-04-15 |
| EP2945940A4 (en) | 2016-07-06 |
| ZA201504902B (en) | 2016-07-27 |
| HK1219734A1 (zh) | 2017-04-13 |
| US9403856B2 (en) | 2016-08-02 |
| CN105246882A (zh) | 2016-01-13 |
| JP2016506916A (ja) | 2016-03-07 |
| US20150336994A1 (en) | 2015-11-26 |
| WO2014113413A1 (en) | 2014-07-24 |
| AU2014207716A1 (en) | 2015-07-23 |
| CA2897055A1 (en) | 2014-07-24 |
| CN110302205A (zh) | 2019-10-08 |
| EP3689886A1 (en) | 2020-08-05 |
| EP2945940B1 (en) | 2020-07-15 |
| CN110305162A (zh) | 2019-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014207716B2 (en) | Bcl-2Bcl-xL inhibitors and therapeutic methods using the same | |
| US8691184B2 (en) | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | |
| AU2012209295A1 (en) | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | |
| AU2013306087B2 (en) | Bivalent inhibitors of IAP proteins and therapeutic methods using the same | |
| US20110319362A1 (en) | Stat3 ligands and therapeutic uses thereof | |
| HK40025523A (en) | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer | |
| HK40008278A (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
| HK40008279A (en) | Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof | |
| HK40008279B (en) | Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof | |
| NZ613504B2 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |